On July 6, 2016, with the recommendation of the Compensation Committee of the Board of Directors (the
) of Biocept, Inc. (the
), the Board approved the following retention awards consisting of restricted stock units (
Michael W. Nall,
President and Chief Executive Officer
Lyle J. Arnold, Ph.D.,
Senior Vice-President of Research & Development
Veena Singh, M.D.,
Senior Vice President and Senior Medical Director
Each of these RSUs were granted pursuant to the Companys Amended and Restated 2013 Equity Incentive Plan. Subject to eac h executive officers continuous service, 100% of each RSU will vest on the 12-month anniversary of the date of grant.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 7, 2016
/s/ Michael W. Nall
Michael W. Nall
Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
On February - Feb. 12, 2018
Sabby Healthcare Master Fund, Ltd. just issued a filing suggesting it has sold all of its Biocept - Feb. 1, 2018
On January - Jan. 30, 2018
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 26, 2018
Registration adding securities to prior Form S-1 registration [Rule 462(b)] - Jan. 26, 2018